Toyota|$18.20 (¥2,910)+2.30%▲ (in JPY terms)
Sony|$22.81 (¥3,648)-0.57%▼ (in JPY terms)
SoftBank|$52.16 (¥8,341)-3.37%▼ (in JPY terms)
MUFG|$19.61 (¥3,135)+2.92%▲ (in JPY terms)
Keyence|$504.55 (¥80,680)+2.99%▲ (in JPY terms)
Nintendo|$46.87 (¥7,494)+0.92%▲ (in JPY terms)
NTT|$0.93 (¥148)+0.20%▲ (in JPY terms)
Takeda|$29.69 (¥4,748)-2.10%▼ (in JPY terms)
Tokyo Electron|$380.73 (¥60,880)+13.35%▲ (in JPY terms)
Recruit|$67.92 (¥10,860)+0.14%▲ (in JPY terms)
ITOCHU|$11.63 (¥1,859)+0.08%▲ (in JPY terms)
Honda|$9.36 (¥1,497)+7.89%▲ (in JPY terms)
Shin-Etsu|$48.54 (¥7,762)+3.87%▲ (in JPY terms)
Tokio Marine|$44.43 (¥7,104)+0.82%▲ (in JPY terms)
Fast Retailing|$494.36 (¥79,050)-0.79%▼ (in JPY terms)
Toyota|$18.20 (¥2,910)+2.30%▲ (in JPY terms)
Sony|$22.81 (¥3,648)-0.57%▼ (in JPY terms)
SoftBank|$52.16 (¥8,341)-3.37%▼ (in JPY terms)
MUFG|$19.61 (¥3,135)+2.92%▲ (in JPY terms)
Keyence|$504.55 (¥80,680)+2.99%▲ (in JPY terms)
Nintendo|$46.87 (¥7,494)+0.92%▲ (in JPY terms)
NTT|$0.93 (¥148)+0.20%▲ (in JPY terms)
Takeda|$29.69 (¥4,748)-2.10%▼ (in JPY terms)
Tokyo Electron|$380.73 (¥60,880)+13.35%▲ (in JPY terms)
Recruit|$67.92 (¥10,860)+0.14%▲ (in JPY terms)
ITOCHU|$11.63 (¥1,859)+0.08%▲ (in JPY terms)
Honda|$9.36 (¥1,497)+7.89%▲ (in JPY terms)
Shin-Etsu|$48.54 (¥7,762)+3.87%▲ (in JPY terms)
Tokio Marine|$44.43 (¥7,104)+0.82%▲ (in JPY terms)
Fast Retailing|$494.36 (¥79,050)-0.79%▼ (in JPY terms)

SUMITOMO CHEMICAL COMPANY,LIMITED “We have released a YouTube video titled "A Close Look at Our Employees' Challenges! ~[A Day in the Life] Taking on Diseases That Couldn't Be Cured with Conventional Medicines! The Challenges of Oligonucleotide Department Members Supporting Cutting-Edge Pharmaceutical Development~".”

by

SUMITOMO CHEMICAL COMPANY,LIMITED “We have released a YouTube video titled "A Close Look at Our Employees' Challenges! ~[A Day in the Life] Taking on Diseases That Couldn't Be Cured with Conventional Medicines! The Challenges of Oligonucleotide Department Members Supporting Cutting-Edge Pharmaceutical Development~".”

AI-Generated Summary

Sumitomo Chemical is highlighting its oligonucleotide drug development capabilities through employee-focused content, signaling strategic investment in next-generation therapeutics as a potential growth driver. This communications effort suggests the company aims to build investor awareness around its pharmaceutical innovation pipeline in an emerging field with significant commercial potential.

This summary is AI-generated based on the release title and may not reflect the full content of the original document.

Tags: JP3401400001SUMITOMO CHEMICAL COMPANY,LIMITED

コメントする

Contact